Revvity Establishes In Vivo Imaging Center of Excellence in North Carolina
Facility designed to advance the next generation of imaging systems
Advertisement
Revvity, Inc. announced the opening of its new in vivo imaging Center of Excellence in Morrisville, North Carolina, the heart of the state’s Research Triangle. The center consolidates Revvity’s expertise and resources to drive R&D innovation and create the next generation of imaging systems backed by AI software tools and other advanced technologies.
The new facility is staffed by R&D teams from across the organization, including software, hardware, and applied biology/applications teams, as well as those specialized in machine learning, optical, microCT, and ultrasound. Combined, these teams will help create opportunities and develop scientific solutions, addressing challenges in disease researchers’ workflows.
“The In Vivo Imaging Center of Excellence will allow Revvity to drive innovation at a faster pace and stay at the forefront of not only in vivo imaging, but also other imaging modalities shaping life sciences worldwide,” said Kevin Quick, vice president of platforms, life sciences. “Having these teams under one roof benefits not only our company, but also the researchers and scientists whom we collaborate with – from teams investigating the progression of cancer and disease, tissue morphology, or therapeutic efficacy.”
The purpose of the site is to advance next-generation instruments, optical, x-ray CT, multi-modal AI analysis software, and ultrasound systems.
Visitors to the center can receive live demos, training on the imaging systems, and meet with field application specialists.
Most read news
Organizations
Other news from the department research and development
These products might interest you
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
QUANTRO Therapeutics extends collaboration with Boehringer Ingelheim - Novel targets in oncology
Giles introduces AI agent to accelerate healthcare and life science research - AI tool connects researchers to verified medical and life sciences global databases, enabling accurate extraction and summarisation of academic papers, journals, and articles
Faster and more reliable crystal structure prediction of organic molecules
Elevated hormone flags liver problems in mice with methylmalonic acidemia - Study findings can immediately be applied to human patients with the disease
Investigational monoclonal antibody to treat Ebola is safe in adults
NIH clinical trial of remdesivir to treat COVID-19 begins
APEIRON’s respiratory drug product to start pilot clinical trial to treat coronavirus disease
CORAT Therapeutics obtained regulatory authorization for clinical phase Ib/II trial with the SARS-CoV-2 neutralizing human antibody COR-101 - COR-101 is a human antibody that blocks virus infection by binding to the spike protein
New muscle therapy gets fast-track boost - Berlin start-up could soon be helping children with previously incurable muscle diseases thanks to an accelerated approval process
SAS accelerates delivery of novel medicines using AI and analytics - Cooperation with AstraZeneca for more innovation in clinical research
Gentle protein purification at the touch of a button - i3 Membrane revolutionizes the separation of biological agents